Information Provided By:
Fly News Breaks for March 29, 2018
AVEO
Mar 29, 2018 | 05:10 EDT
Piper Jaffray analyst Edward Tenthoff expects Aveo Oncology to report Phase III Tivo-3 data in third-line renal cell carcinoma in Q2. The analyst is confident tivozanib will achieve a statistically significant survival benefit over Nexavar and recommeds buying the stock ahead of the readout. Positive data will enable Aveo to respond to the 2013 tivozanib complete response letter with potential FDA approval in 2019, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $5 price target.
News For AVEO From the Last 2 Days
There are no results for your query AVEO